Replies to post #108217 on Biotech Values

[mcbio]

RIGL does have a JAK drug though I doubt it is currently being developed for arthritis. Maybe they have plans for that indication down the road.

That's correct, RIGL does have a JAK3 drug, but they are not developing it for arthritis. The focus is transplant rejection (see Item 6 of #msg-55725991) and I believe they are also trying to outlicense the drug as a topical treatment for psoriasis.

And if AZN is a syk inhibitor then its not a late stage jak drug.

Not defending the writer:)

LOL